Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping
Prnewswire·2026-02-19 13:30
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping [Accessibility Statement] Skip NavigationFoundational Patent Strengthens AI Moat Across Multimodal Data Standardization, Disease Stratification and Gene MappingSACRAMENTO, Calif., Feb. 19, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven biotechnology company advancing precision therapeutics in central nervous system (CNS) disorders and oncology, as well as solutions for ...